Cellid Raised 10 Billion Won by Diluting Shares 16 Percent
A single third-party placement filed today adds 4.8 million new Cellid shares to a base of 29.5 million — 16.26% dilution, with the company's own filing marking 9.999 billion of the roughly 10 billion won raised as general operating funds.
AI-assisted, human-reviewed sourcing. Figures are pulled programmatically from the official sources listed at the end of this article and checked by an editor before publication.
dartbiotechkoreadisclosuredilutionrights-issue
Cellid (KOSDAQ: 299660) filed a decision to raise capital through a third-party share placement with Korea’s Financial Supervisory Service on 21 September, 2026. The filing adds 4,796,163 new common shares to a pre-issuance base of 29,502,977 — 16.26% dilution by the filing’s own two figures.
What the filing says
| Field | Value |
|---|---|
| New shares issued | 4,796,163 |
| Shares outstanding before issuance | 29,502,977 |
| Dilution | 16.26% |
| Face value per share | ₩500 |
| Issuance method | Third-party allotment (제3자배정증자) |
| Use of proceeds — operating funds | ₩9,999,999,855 |
| Use of proceeds — every other listed category | ₩0 |
Every won of the roughly 10 billion won raised is booked to one line: general operating funds. The filing’s use-of-proceeds table lists five other categories — facility investment, business acquisition, debt repayment, other securities purchase, and a miscellaneous line — and all five read zero.
What we did not verify
The structured API response we pulled this from does not carry the name of the party receiving the new shares, or the issue price. Both are disclosed elsewhere in the full DART filing body, which we did not parse for this piece. We also have no information here on why Cellid needs the funds, or how this raise compares to its recent cash position — a single capital-increase filing describes one event, not the company’s overall financial health.
This is not investment advice. Figures are drawn from an official regulatory filing and are presented for data-quality reporting, not as a trading signal.
Data & Verification Notes
- Data as of
- Sources
- Financial Services Commission (Republic of Korea) / DART — Open DART API — piicDecsn (Decision on Paid-in Capital Increase), filed 21 September 2026 (rcept_no 20260921000434)
- Cross-checks
- The filing states 4,796,163 new common shares against a pre-issuance total of 29,502,977 shares — 16.26% dilution by our own calculation from the filing's own two figures, matching a third-party allotment (제3자배정증자).
- Face value per share is listed at 500 won. Use-of-proceeds fields in the filing put 9,999,999,855 won under general operating funds (운영자금) and 0 won under every other listed category (facility investment, business acquisition, debt repayment, other securities purchase).
- Excluded figures
- The identity of the third-party allottee — the filing we pulled does not carry that field; it is disclosed in the full DART report body, not the structured API response we used.
- Any view on what Cellid needs the operating funds for, or the company's cash runway before this raise. We report the filing, not the company's broader financial condition.
- The issue price and whether it represents a discount to the recent trading price — not present in this API response.
- Instruments
- 299660
The full dataset behind these figures — every listed company, every row — is available to license. SeoulMarkets data for licence →
Not investment advice. SMarkets publishes data journalism for general information only. Nothing here is investment advice, a recommendation, or an offer to buy or sell any security — any investment you make is at your own risk and responsibility. Figures are derived from official public data sources and may be revised by the issuing agency. Verify independently before acting.
← More Equities